Focusing on study subgroups, those that developed HCC by the end of the follow-up had a decline in sCD163 (p = 0.03) and ATX (p = 0.03) that was sustained at SVR12 (Figure 4). The gene discussed is CD163; the disease is hepatocellular carcinoma.